Poland· PL-100309250
Competact
A metformin and pioglitazone product containing pioglitazoni hydrochloridum + metformini hydrochloridum, registered in Poland by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Metformin and pioglitazone is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD05 (metformin and pioglitazone), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Metformin and pioglitazone · ATC A10BD05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Pioglitazoni hydrochloridum + Metformini hydrochloridum
- Manufacturer
- CHEPLAPHARM Arzneimittel GmbH
- Country
- Poland (PL)
- ATC code
- A10BD05
- ATC class
- Metformin and pioglitazone
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and pioglitazone.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and pioglitazone · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and pioglitazone in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCOMPETACTCHEPLAPHARM Arzneimittel GmbH, Greifswald
- United StatesActoplus MetTakeda Pharmaceuticals America, Inc.
- United KingdomCompetact 15mg/850mg tabletsMawdsley-Brooks & Company Ltd
- ItalyCOMPETACTCHEPLAPHARM ARZNEIMITTEL GMBH
- SpainCOMPETACT 15 mg/850 mg COMPRIMIDOS RECUBIERTOS CON PELICULATakeda Pharma A/S
- FinlandCompetactOrifarm Oy
- SwitzerlandCompetact
- IcelandCompetactCHEPLAPHARM Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Bulgaria · Пизона Комби
- Czechia · Novapio Plus
- Spain · Pioglitazona/Metformina Aristo
- United Kingdom (Northern Ireland) · Pioglitazone And Metformin Hydrochloride Clydesdale Pharma, Pioglitazone/Metformin Torrent Pharma (Uk)
- Greece · Pioglitazone/Metformin Genepharm
- Croatia · Novapio Plus
- Hungary · Pioglitazone / Metformin Genepharm
- Iceland · Competact
- Italy · Pioglitazone E Metformina Docgen, Pioglitazone E Metformina Eg
- Liechtenstein · Competact
- Norway · Competact
- Portugal · Metformina + Pioglitazona Biofarmoz, Metformina + Pioglitazona Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5bd49007-0805-4177-a5f6-9ad38fae4f53 GET /v1/drugs/5bd49007-0805-4177-a5f6-9ad38fae4f53?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "15 mg + 850 mg",
"packaging": "Rp ¦ Skasowane ¦ EU/1/06/354/001 ¦ 18076\n14 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/002 ¦ 32619\n28 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/003 ¦ 34344\n30 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/004 ¦ 35590\n50 tabl.\nRp ¦ EU/1/06/354/005 ¦ 40897\n56 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/006 ¦ 42268\n60 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/007 ¦ 43194\n90 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/008 ¦ 43743\n98 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/009 ¦ 45867\n180 tabl.\nRp ¦ EU/1/06/354/010 ¦ 46173\n112 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/011 ¦ 46426\n196 tabl.\nRp ¦ Skasowane ¦ EU/1/06/354/012 ¦ 88581\n60 tabl.",
"substance": "Pioglitazoni hydrochloridum 15 mg + Metformini hydrochloridum 850 mg",
"common_name": "Pioglitazoni hydrochloridum + Metformini hydrochloridum",
"pl_product_id": "100309250",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about metformin and pioglitazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.